About GNA11

The GNA11 gene (G Protein Subunit Alpha 11) on chromosome 19p13 GNA11 Q209 mutations in the Ras-like domain occur in uveal melanoma, blue nevi, and are mutually exclusive with GNAQ mutations. Key targets include Exons 4–7 (Ras-like domain, helical domain) for comprehensive mutation screening.

Mutations: Q209L, Q209P, R183C | GC content: 58% | Target exons: Exons 4–7 (Ras-like domain, helical domain)

GNA11 Primer Design Challenges

  • Q209 hotspot: Glutamine 209 mutations in exon 5 ablate GTPase activity causing constitutive Gq signaling
  • Elevated GC (58%): The helical domain (exons 6–7) has high GC requiring careful primer Tm optimization
  • Mutual exclusivity with GNAQ: Parallel testing for both GNA11 and GNAQ requires comparable primer efficiencies for multiplexing

Recommended Primer Design Parameters for GNA11

ParameterStandard ExonsGC-Rich Regions (≥58%)
Primer length20–22 nt22–25 nt
GC content45–55%50–60%
Tm58–62°C60–65°C
Amplicon size150–300 bp180–350 bp
Annealing temp58–60°C60–64°C (touchdown)
PCR additiveStandardAdd 5–10% DMSO or betaine

Recommended Primer Sequences for GNA11

Target RegionForward Primer (5′→3′)Reverse Primer (5′→3′)Amplicon
Exon 5 (Q209)5′-TGACCTGCCTCAACTGACTC-3′5′-CAGAAGGCAGCTGGACATTG-3′192 bp
Exon 4 (R183)5′-CTTGCAGTGGGCCTGTATGT-3′5′-GACACAGTCCATGACCTCCC-3′179 bp

Key SNPs to Avoid in Primer Binding Sites

When designing GNA11 primers, avoid these clinically significant variants:

  • rs121913746 (Q209L) — Exon 5 uveal melanoma activating mutation
  • rs121913749 (R183C) — Exon 4 GTPase domain in blue nevi

Clinical Validation Required
All GNA11 primers designed with VigyanLLM are for research use only. Clinical diagnostic applications require additional wet-lab validation, Sanger sequencing confirmation, and regulatory approval before patient use.

Design GNA11 Primers Now

Pre-configured with GNA11-specific parameters. Use our primer design, Tm calculator, and GC content tools for optimal results.

Design GNA11 Primers → Tm Calculator GC Calculator